Core Points - AIM ImmunoTech Inc. will participate in the 2025 Maxim Growth Summit on October 22-23, 2025, in New York, NY, which focuses on industry trends and advancements [1] - Management will be available for in-person one-on-one meetings with registered investors during the conference [2] - AIM ImmunoTech is an immuno-pharma company developing therapeutics for cancers, immune disorders, and viral diseases, with its lead product being Ampligen, currently in Phase 2 clinical trials for metastatic pancreatic cancer in collaboration with AstraZeneca [4] Company Information - AIM ImmunoTech Inc. specializes in research and development of therapeutics targeting multiple diseases, including COVID-19 [4] - The company's lead product, Ampligen (rintatolimod), is a first-in-class investigational drug that acts as a dsRNA and TLR3 agonist [4] - AIM ImmunoTech is focused on broad-spectrum activity in clinical trials, particularly in combination therapies for cancer treatment [4] Event Information - The Maxim Growth Summit is organized by Maxim Group LLC, a full-service investment banking and wealth management firm based in New York [3] - The summit will feature industry leaders and innovators discussing the latest trends across various sectors [1] - For more details on the summit agenda and AIM's presentation, interested parties can visit the respective websites [2]

Core Viewpoint - AIM ImmunoTech Inc. has received a patent from the Japan Patent Office for the use of Ampligen in combination with checkpoint inhibitors for cancer treatment, enhancing its international market protection and potential for revenue growth [1][2]. Group 1: Patent and Market Implications - The Japan patent strengthens AIM's intellectual property portfolio in a significant oncology market, expiring on December 20, 2039, and enhances exclusivity for combination therapies targeting high-need cancer indications [2][4]. - The patent claims cover a wide range of cancer types, including pancreatic, skin, colorectal, ovarian, melanoma, breast, head and neck, bladder, renal cell carcinoma, and lung cancer, along with specific dosing regimens and administration routes [3]. Group 2: Clinical Development and Collaborations - AIM is advancing its clinical pipeline with Ampligen in combination with AstraZeneca's durvalumab for metastatic pancreatic cancer, showing promising results in Progression-Free Survival and Overall Survival [5]. - A Phase 2 study with Merck Sharp & Dohme LLC combining Ampligen with Keytruda for advanced recurrent ovarian cancer has been completed, with final data expected soon [6]. Group 3: Company Overview - AIM ImmunoTech Inc. focuses on developing therapeutics for various cancers, immune disorders, and viral diseases, with Ampligen being a first-in-class investigational drug that acts as a TLR3 agonist [7].

Core Insights - AIM ImmunoTech Inc. presented positive progress on its lead program Ampligen for pancreatic cancer at the 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care, highlighting improvements in Progression-Free Survival and Overall Survival from the DURIPANC clinical trial and Early Access Program [1][2][3] Company Overview - AIM ImmunoTech Inc. is focused on developing therapeutics for various cancers, immune disorders, and viral diseases, with its lead product being Ampligen, a first-in-class investigational drug [5] Clinical Trials and Data - The Phase 2 DURIPANC clinical trial is currently evaluating the combination of Ampligen and AstraZeneca's anti-PD-L1 immune checkpoint inhibitor durvalumab for late-stage metastatic pancreatic cancer patients [3] - The clinical data presented indicates a strong potential for Ampligen in treating late-stage pancreatic cancer, addressing a significant unmet medical need [3] Regulatory and Market Position - Ampligen has patent protection for its combination therapy in the U.S. until 2039 and has received orphan drug designations in both the U.S. and EU, which will provide market protections for an approved drug [3]

Core Insights - Lisata Therapeutics and WARPNINE have completed patient enrollment in the Phase 1b/2a iLSTA trial, evaluating certepetide in combination with standard-of-care chemotherapy and immunotherapy for locally advanced non-resectable pancreatic ductal adenocarcinoma (PDAC) [1][2] - The trial is significant as it targets an earlier stage of PDAC, where immunotherapy has been largely ineffective [2] - Preliminary data from the trial presented at ESMO-GI indicated a 60% overall response rate and a 100% overall disease control rate after four treatment cycles [3][4] Company Overview - Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases [7] - Certepetide, the company's proprietary product candidate, is designed to enhance the delivery of anti-cancer drugs to solid tumors and has shown favorable safety and clinical activity in trials [6][7] - The company has received multiple designations for certepetide, including Fast Track and Orphan Drug Designations for pancreatic cancer in the U.S. and E.U. [6] Trial Details - The iLSTA trial is randomized, single-blind, and conducted at St John of God Subiaco Hospital, a leading center for clinical research in Australia [2][3] - Participants were divided into three cohorts, with varying combinations of standard-of-care chemotherapy and immunotherapy [2] - The trial aims to assess the efficacy of certepetide in improving treatment outcomes for patients with locally advanced PDAC [2][4] Preliminary Data Highlights - After four treatment cycles, 13 out of 20 participants showed a partial response, and one participant exhibited a complete response [3] - 16 out of 20 participants experienced a decrease in CA19-9 levels, a tumor marker, with several showing significant reductions [3] - No participants showed an increase in tumor size, indicating a positive response to the treatment [3] Collaboration and Support - The collaboration between Lisata and WARPNINE combines global expertise with local clinical execution to address urgent needs in pancreatic cancer treatment [2] - AstraZeneca is involved in providing drug supply, enhancing the trial's operational capabilities [2] - The successful completion of patient enrollment reflects the commitment of both organizations to advance treatment options for patients with PDAC [4]